https://www.biospace.com/article/gene-therapy-approvals-to-ramp-up-in-2024-amid-manufacturing-cost-challenges/
A possible 17 approvals next year in cell and gene therapies.
"Regulators in the U.S. gave the greenlight in 2023 to five gene therapies for rare genetic diseases and in 2024 could see an additional five approved by the FDA, as well as the first-ever approval of adoptive cell therapy for solid tumors and the first U.S. approval of an allogeneic T-cell therapy"
https://podcast.radionz.co.nz/sat/sat-20231104-0905-engineering_immune_cells_to_kill_cancer-128.mp3
Dr Carl June ( chm 2101) touches briefly on it here. There are roughly 1000 CAR T trials ongoing atm.
It's a modern day oncology gold rush. I'm here because of management and CHM assets.
JPM 2024: On the Ground in San Francisco
https://www.biospace.com/article/jpm-2024-on-the-ground-in-san-francisco/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |